Advertisement


Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis

2025 ASCO Annual Meeting

Advertisement

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Here at ASCO, we're presenting the overall survival results of the ANAVO-120 trial. This is a trial for patients with metastatic hormone receptor-positive, HER2-negative breast cancer that has got PIK3CA mutations and specifically for patients that are relapsing on endocrine therapy. We know that this is an aggressive type of breast cancer and we're very much in need of new therapies. And so the ANAVO-120 trial randomized these patients in the first-line setting to the standard of care, which was fulvestrant and palbociclib, or the addition of the PI3 kinase inhibitor inavolisib in the triplet. Inavolisib is a novel PI3 kinase inhibitor. It inhibits PIK3CA alpha, but also it degrades the alpha mutant protein and that probably improves the therapeutic window with inavolisib compared to other PI3 kinase inhibitors. And very importantly, inavolisib is combinable with fulvestrant and palbociclib at the maximum single agent doses. And so what we're doing in that triple combination is we're targeting the estrogen receptor, CDK4/6, and the PI3 kinase inhibitor. And by targeting all of these three key aspects of this type of breast cancer, we're really starting to get really significant efficacy. So in the primary readout of ANAVO-120, we demonstrated that adding in inavolisib substantially improved progression-free survival. And now with longer follow-up, we're also demonstrating that adding in inavolisib improved overall survival with a hazard ratio of 0.67, passing the statistical significance barrier. So that's improving overall survival by 33% on average. A median improvement is 7 months. But we also can look at some other really important endpoints in the study, in particular time to first use of chemotherapy. I mean, this is an endpoint that is very important for people, and the addition of inavolisib delayed the time to chemotherapy on average by almost two years. Now why are we seeing such a big improvement in the study? Partly it's that first-line efficacy substantially improving PFS by over half, as well as a substantial improvement in the response rate. And that of course carries through to delaying time to chemotherapy, but also because we're seeing such a reduction in tumor burden with the triplet that also enabled people in the second line to avoid chemotherapy more often. And it's all translated through to that almost doubling in time to chemotherapy. So this is potentially a really important new treatment option for these patients who've relapsed on endocrine therapy with PIK3CA mutant breast cancer.

Related Videos

Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Lung Cancer

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract 8001). 

Leukemia

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 

Advertisement

Advertisement




Advertisement